التفاصيل البيبلوغرافية
| العنوان: |
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study |
| المؤلفون: |
Passaro, A., Wang, J., Wang, Y., Lee, S.-H., Melosky, B., Shih, J.-Y., Azuma, K., Juan-Vidal, O., Cobo, M., Felip, E., Girard, N., Cortot, A.B., Califano, R., Cappuzzo, F., Owen, S., Popat, S., Tan, J.-L., Salinas, J., Tomasini, P., Gentzler, R.D., William, W.N., Jr., Reckamp, K.L., Takahashi, T., Ganguly, S., Kowalski, D.M., Bearz, A., MacKean, M., Barala, P., Bourla, A.B., Girvin, A., Greger, J., Millington, D., Withelder, M., Xie, J., Sun, T., Shah, S., Diorio, B., Knoblauch, R.E., Bauml, J.M., Campelo, R.G., Cho, B.C. |
| المصدر: |
In Annals of Oncology January 2024 35(1):77-90 |
| قاعدة البيانات: |
ScienceDirect |
